Disc Medicine Analyst Ratings
Buy Rating Affirmed: Strong Phase 2 Results and Strategic FDA Engagement Bolster Confidence in Disc Medicine's Pipeline
BMO Capital Reiterates Outperform on Disc Medicine, Raises Price Target to $70
Wedbush Raises Disc Medicine Price Target to $57 From $43, Maintains Outperform Rating
Disc Medicine Analyst Ratings
Disc Medicine Analyst Ratings
Disc Medicine Analyst Ratings
Cantor Fitzgerald Keeps Their Buy Rating on Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Disc Medicine Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)
Optimistic Buy Rating for Disc Medicine Amid Anticipated Study Results and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
Disc Medicine Analyst Ratings
Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Intuitive Surgical (ISRG) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating
Disc Medicine Analyst Ratings
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept